Wilson R, McKillop J H, Pearson D W, Cuthbert G F, Thomson J A
J Nucl Med. 1985 Sep;26(9):1024-8.
In 49 patients with Graves' disease, the 20-min thyroidal uptake of 99mTc and serum levels of thyroid stimulating hormone (TSH) receptor antibody were estimated at presentation and at intervals during a 1-yr course of carbimazole and triiodothyronine. In the 12 mo after cessation of therapy, 29 patients developed recurrent thyrotoxicosis. Thyroidal 99mTc uptake had a poor predictive value for recurrence of thyrotoxicosis, both at presentation and during therapy. A very high level of TSH receptor antibody was present in seven patients at presentation, all of whom relapsed on withdrawing therapy. An abnormal value of TSH receptor antibody at the end of the course of medical therapy was present in 24/29 (83%) patients who relapsed and in 1/20 (5%) patients who remained euthyroid 1 yr after stopping antithyroid drugs.
对49例格雷夫斯病患者，在就诊时以及在为期1年的卡比马唑和三碘甲状腺原氨酸治疗过程中间隔性地评估其99mTc甲状腺摄取率以及促甲状腺激素（TSH）受体抗体的血清水平。在治疗停止后的12个月内，29例患者出现了复发性甲状腺毒症。无论是在就诊时还是治疗期间，甲状腺99mTc摄取率对甲状腺毒症复发的预测价值都很低。就诊时7例患者的TSH受体抗体水平非常高，所有这些患者在停药后均复发。药物治疗结束时，29例复发患者中有24例（83%）TSH受体抗体值异常，而在停用抗甲状腺药物1年后仍处于甲状腺功能正常状态的20例患者中有1例（5%）TSH受体抗体值异常。
